Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Disitamab vedotin | Pfizer Oncology Development Website
New FDA-Approved ADC: Disitamab Vedotin for Bladder Cancer - BOC Sciences
ASCO 2024: Phase 3 Study of Disitamab Vedotin with Pembrolizumab vs ...
Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive ...
Aidixi Disitamab Vedotin Of Injection | HER2-Overexpressing
Disitamab Vedotin Of Injection: Solid Tumours Treatment
Frontiers | Disitamab vedotin combined with pyrotinib as salvage ...
ESMO 2025: Discussant – Disitamab Vedotin plus Toripalimab Versus ...
Disitamab Vedotin 维迪西妥单抗 爱地希说明书_用法用量_副作用-海南特药-盛诺一家
Disitamab Vedotin 纬迪西妥单抗 爱地希 (RC48)_印度肿瘤药房！
Disitamab Vedotin
Full article: SGNDV-001: disitamab vedotin with pembrolizumab in HER2 ...
(PDF) Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in ...
IND for RemeGen's Disitamab Vedotin Marks Important Milestone for the ...
ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in ...
(PDF) Disitamab vedotin in combination with immune checkpoint ...
Disitamab vedotin （RC-48） | 维迪西妥单抗 | 抗肿瘤 | TargetMol
Disitamab vedotin | Antibody-Drug Conjugates (ADCs) | EGFR | TargetMol
ASCO GU 2025: Neoadjuvant Treatment with Disitamab Vedotin plus ...
(PDF) Disitamab Vedotin (RC48) combined with bevacizumab for treatment ...
Medchemexpress LLC HY-P9985 5mg , Disitamab vedotin CAS:2136633-23-1 ...
New Drug: Disitamab Vedotin plus Toripalimab in HER2-Expressing ...
ESMO 2024: Preliminary Efficacy And Safety Of Disitamab Vedotin With ...
(PDF) Application of disitamab vedotin in the multiline treatment of ...
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced ...
Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 ...
AiDiXi ( Disitamab Vedotin ) | 60mg | Inyección - DengYuePharma
Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in ...
Revolutionary Phase 3 Trial Results for Disitamab Vedotin in Urothelial ...
(PDF) Disitamab vedotin (RC48) plus toripalimab for HER2-expressing ...
Study of Disitamab Vedotin and Pembrolizumab for Patients with Advanced ...
Disitamab vedotin - Wikipedia
Disitamab Vedotin – Application in Therapy and Current Clinical Research
Frontiers | Disitamab Vedotin plus anti-PD-1 antibody show good ...
Disitamab Vedotin Antibody Drug at ₹ 4200/piece | Biochemistry reagents ...
(PDF) Neoadjuvant therapy with Disitamab vedotin in treating muscle ...
Disitamab vedotin plus toripalimab in patients with locally advanced or ...
On-site from ESMO Asia | Professor Liangyou Gu: Disitamab Vedotin Plus ...
(PDF) Efficacy of disitamab vedotin in non-small cell lung cancer with ...
Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in ...
ASCO GU 2025: Preliminary Efficacy and Safety of Disitamab Vedotin ...
RemeGen's Disitamab Vedotin Receives NMPA Approval for HER2+ Breast ...
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48 ...
(PDF) Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer ...
Disitamab Vedotin + Pembrolizumab vs Chemotherapy for Bladder Cancer ...
Study of Disitamab Vedotin and Tucatinib for Patients with Advanced ...
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy ...
(PDF) Disitamab vedotin: a novel antibody-drug conjugates for cancer ...
(PDF) Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in ...
(PDF) Disitamab Vedotin, a HER2-directed Antibody Drug-Conjugate, in ...
Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients ...
Disitamab Vedotin–Based Combination Strategy Redefines First-Line ...
Pharmaceutical Insights: Disitamab Vedotin's R&D Progress and its ...
Disitamab vedotin/RC48 2136633-23-1 抗体偶联药物 针对HER2的ADC药物 维迪西妥单抗价格_品牌 ...
Disitamab | AxisPharm
Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer
ASCO 2025: Trials-in-Progress – PUNCH03: A Phase II Study of Disitamab ...
The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based ...
First-Line Disitamab Vedotin/Toripalimab Shows Benefit in HER2+ la/mUC ...
AUA 2025: Postoperative Adjuvant Treatment of HER2-Overexpressing Upper ...
维迪西妥单抗(Disitamab vedotin)说明书及用法用量-肿瘤药品网
Kadcyla - Top-Selling Antibody Drug Conjugate (ADC) | Biopharma PEG
深度盘点FDA批准用于癌症治疗的抗体偶联药物（ADC） - 知乎
Frontiers | Antibody-Drug Conjugates Targeting the Human Epidermal ...
ASCO GU 2025: Better Together? Exploring Novel Drug Combinations with ...
Oncology Letters
ASCO GU 2025: Targeting Bladder Cancer with Antibody Drug Conjugates
ASCO GU 2025: HER2 Antibody Drug Conjugate Therapy: A New Frontier in ...
ESMO 2022: Phase 2 Clinical Study Evaluating the Efficacy and Safety of ...
Clinicopathological and molecular correlates of clinical benefit from ...
荣昌生物制药（烟台）股份有限公司_荣昌生物
PPT - Antibody-drug Conjugates for HER2-Positive Gastric Cancer ...
ESMO 2025: Efficacy and Safety Results from Formula-01: A Phase II ...
ErbB2/Her2 (Disitamab Vedotin) Antibody - Azide and BSA Free (NBP3 ...
已上市ADC：专利布局全景分析
| Structures of trastuzumab emtansine (T-DM1), trastuzumab deruxtecan ...
Tisotumab vedotin; First FDA Approved Antibody-drug Conjugate for ...
Assessment of HER2 status in extramammary Paget disease and its ...
IBCN 2024: Mechanisms of Resistance to Antibody Drug Conjugates
IBCN 2024: ADC Toxicity, Management and Clinical Trial Updates
